These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34971394)

  • 21. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.
    Averna M; Cefalù AB; Stefanutti C; Di Giacomo S; Sirtori CR; Vigna G
    Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):36-44. PubMed ID: 26723464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lomitapide for the management of homozygous familial hypercholesterolemia.
    deGoma EM
    Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
    Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.
    Cuchel M; Bruckert E; Ginsberg HN; Raal FJ; Santos RD; Hegele RA; Kuivenhoven JA; Nordestgaard BG; Descamps OS; Steinhagen-Thiessen E; Tybjærg-Hansen A; Watts GF; Averna M; Boileau C; Borén J; Catapano AL; Defesche JC; Hovingh GK; Humphries SE; Kovanen PT; Masana L; Pajukanta P; Parhofer KG; Ray KK; Stalenhoef AF; Stroes E; Taskinen MR; Wiegman A; Wiklund O; Chapman MJ;
    Eur Heart J; 2014 Aug; 35(32):2146-57. PubMed ID: 25053660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Lomitapide in Hypercholesterolemia.
    Liu X; Men P; Wang Y; Zhai S; Zhao Z; Liu G
    Am J Cardiovasc Drugs; 2017 Aug; 17(4):299-309. PubMed ID: 28255870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
    Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
    Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
    Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P
    J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia.
    Harada-Shiba M; Ikewaki K; Nohara A; Otsubo Y; Yanagi K; Yoshida M; Chang Q; Foulds P
    J Atheroscler Thromb; 2017 Apr; 24(4):402-411. PubMed ID: 28154305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
    Davis KA; Miyares MA
    Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance.
    Cuchel M; Raal FJ; Hegele RA; Al-Rasadi K; Arca M; Averna M; Bruckert E; Freiberger T; Gaudet D; Harada-Shiba M; Hudgins LC; Kayikcioglu M; Masana L; Parhofer KG; Roeters van Lennep JE; Santos RD; Stroes ESG; Watts GF; Wiegman A; Stock JK; Tokgözoğlu LS; Catapano AL; Ray KK
    Eur Heart J; 2023 Jul; 44(25):2277-2291. PubMed ID: 37130090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
    Cuchel M; Meagher EA; du Toit Theron H; Blom DJ; Marais AD; Hegele RA; Averna MR; Sirtori CR; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Du Plessis AM; Propert KJ; Sasiela WJ; Bloedon LT; Rader DJ;
    Lancet; 2013 Jan; 381(9860):40-6. PubMed ID: 23122768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P
    Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of homozygous familial hypercholesterolaemia in two brothers.
    Real J; Arbona C; Goterris R; Ascaso JF
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29306853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
    Vuorio A; Tikkanen MJ; Kovanen PT
    Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.
    Blom DJ; Fayad ZA; Kastelein JJ; Larrey D; Makris L; Schwamlein C; Bloeden L; Underberg J;
    J Clin Lipidol; 2016; 10(2):273-82. PubMed ID: 27055957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
    Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
    J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study.
    Masana L; Zambon A; Schmitt CP; Taylan C; Driemeyer J; Cohen H; Buonuomo PS; Alashwal A; Al-Dubayee M; Kholaif N; Diaz-Diaz JL; Maatouk F; Martinez-Hervas S; Mangal B; Löwe S; Cunningham T
    Lancet Diabetes Endocrinol; 2024 Dec; 12(12):880-889. PubMed ID: 39426393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.